Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure by Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes

Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure by Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes

Post-transplant lymphoproliferative disease (PTLD) represents a serious complication following allogeneic hematopoietic stem cell transplantation (alloHSCT). Previously, survival rates of PTLD have improved due to the introduction of rituximab. However, reports on curative management of refractory P...

Full description

Bibliographic Details
Main Authors: Thomas Mika, Katharina Strate, Swetlana Ladigan, Clemens Aigner, Uwe Schlegel, Iris Tischoff, Sabine Tischer-Zimmermann, Britta Eiz-Vesper, Britta Maecker-Kolhoff, Roland Schroers
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-12-01
Series:Frontiers in Medicine
Subjects:
PTLD
alloHSCT
aggressive lymphoma
brentuximab vedotin (BV)
third-party EBV-specific T-lymphocytes
Online Access:https://www.frontiersin.org/article/10.3389/fmed.2019.00295/full

Internet

https://www.frontiersin.org/article/10.3389/fmed.2019.00295/full

Similar Items